Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas

Virchows Archiv

Volumn 451, Issue 6, 2007, Pages 999-1007

  Salas, Sébastien ^a   Bartoli, Catherine ^b   Deville, Jean Laurent ^a   Gaudart, Jean ^a   Fina, Fréderic ^c   Calisti, Arlette ^b   Bollini, Gérard ^a   Curvale, Georges ^d   Gentet, Jean Claude ^a   Duffaud, Florence ^a   Figarella Branger, Dominique ^a,b   Bouvier, Corinne ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c IFR Jean Roche   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Smooth muscle actin; CD44H; Ezrin; Osteosarcoma; Survival

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; EZRIN; MESSENGER RNA; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG MEGADOSE; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR BIOPSY;

ACTINS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; CYTOSKELETAL PROTEINS; FEMALE; FRANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM METASTASIS; OSTEOSARCOMA; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 36448991176     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-007-0474-8     Document Type: Article

References (43)

1. Antonescu CR, Erlandson RA, Huvos AG (1997) Primary leiomyosarcoma of bone: a clinicopathologic, immunohistochemical, and ultrastructural study of 33 patients and a literature review. Am J Surg Pathol 21:1281-1294
2. Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C, Manfrini M (1997) Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 79:245-254
3. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848-858
4. Bouvier-Labit C, Liprandi A, Monti G, Pellissier JF, Figarella-Branger D (2002) CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. J Neurooncol 60:127-134
5. Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, Maale GE, Spanier S, Neff JR (1997) Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95:74-87
6. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
7. Eikmans M, Baelde HJ, Hagen EC, Paul LC, Eilers PH, De Heer E, Bruijn JA (2003) Renal mRNA levels as prognostic tools in kidney diseases. J Am Soc Nephrol 14:899-907
8. Greenland S, Mickey RM (1989) Re: "The impact of confounder selection criteria on effect estimation. Am J Epidemiol 130:1066
9. Harris MB, Gieser P, Goorin AM, Ayala A, Shochat SJ, Ferguson WS, Holbrook T, Link MP (1998) Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 16:3641-3648
10. Hasegawa T, Hirose T, Seki K, Hizawa K, Ishii S, Wakabayashi J (1997) Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas. Cancer Detect Prev 21:280-287
11. Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10:201-204
12. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O (2005) Ezrin in primary cutaneous melanoma. Mod Pathol 18:503-510
13. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750-3759
14. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182-186
15. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH (2002) Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 396:184-190
16. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG (2007) Ezrin Expression Predicts Survival in Stage IIB Osteosarcomas. Clin Orthop Relat Res 459:229-236
17. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235-240
18. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H (1999) Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 125:646-652
19. Le Deley M, Guinebretiere J, Gentet J, Pacquement H, Pichon F, Marec-Berard P, Entz-Werle N, Schmitt C, Brugieres L, Vanel D, Dupouy N, Tabone M et al (2007) SFOP OS94: a randomised trial comparing preoperative high-dose Methotrexate plus Doxorubicine to high-dose Methotrexate plus Etoposide and Ifosfamide in osteosarcoma patients. European J Cancer 43:752-761
20. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606
21. Mangeat P, Roy C, Martin M (1999) ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9:187-192
22. Martin TA, Harrison G, Mansel RE, Jiang WG (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46:165-186
23. Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin North Am 44:973-989
24. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15
25. Nathrath MH, Kuosaite V, Rosemann M, Kremer M, Poremba C, Wakana S, Yanagi M, Nathrath WB, Hofler H, Imai K, Atkinson MJ (2002) Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man. Oncogene 21:5975-5980
26. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P (2004) Expression of ezrin in prostatic intraepithelial neoplasia. Urology 63:609-612
27. Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, Park YK (2006) Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 202:509-515
28. Peng TS, Qiu JS, Wu HX, Liang HZ, Luo CQ (2002) [Expressions of CD44s, MMP-9, and Ki-67: possible association with invasion, metastasis, and recurrence of osteosarcoma]. Ai Zheng 21:745-750
29. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15:76-84
30. Rocchi P, Muracciole X, Fina F, Mulholland DJ, Karsenty G, Palmari J, Ouafik L, Bladou F, Martin PM (2004) Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 23:9111-9119
31. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230
32. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177
33. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP (1991) Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9:1766-1775
34. Shiratori H, Koshino T, Uesugi M, Nitto H, Saito T (2001) Acceleration of lung metastasis by up-regulation of CD44 expression in osteosarcoma-derived cell transplanted mice. Cancer Lett 170:177-182
35. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S et al (1995) Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 55:1334-1338
36. Taylor WF, Ivins JC, Unni KK, Beabout JW, Golenzer HJ, Black LE (1989) Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst 81:21-30
37. Vaheri A, Carpen O, Heiska L, Helander TS, Jaaskelainen J, Majander-Nordenswan P, Sainio M, Timonen T, Turunen O (1997) The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9:659-666
38. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65:2406-2411
39. Watanabe K, Tajino T, Sekiguchi M, Suzuki T (2000) h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors. Am J Clin Pathol 113:663-668
40. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW (2002) Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62:2281-2286
41. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11:6198-6204
42. Yamamura H, Yoshikawa H, Tatsuta M, Akedo H, Takahashi K (1998) Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer 79:245-250
43. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10:175-181